Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 210(3): 263-272, 2022 12 31.
Artigo em Inglês | MEDLINE | ID: mdl-35960996

RESUMO

Obesity increases the risk of type 2 diabetes mellitus, cardiovascular disease, fatty liver disease, and cancer. It is also linked with more severe complications from infections, including COVID-19, and poor vaccine responses. Chronic, low-grade inflammation and associated immune perturbations play an important role in determining morbidity in people living with obesity. The contribution of B cells to immune dysregulation and meta-inflammation associated with obesity has been documented by studies over the past decade. With a focus on human studies, here we consolidate the observations demonstrating that there is altered B cell subset composition, differentiation, and function both systemically and in the adipose tissue of individuals living with obesity. Finally, we discuss the potential factors that drive B cell dysfunction in obesity and propose a model by which altered B cell subset composition in obesity underlies dysfunctional B cell responses to novel pathogens.


Assuntos
COVID-19 , Diabetes Mellitus Tipo 2 , Humanos , Diabetes Mellitus Tipo 2/metabolismo , Obesidade/complicações , Obesidade/metabolismo , Inflamação , Tecido Adiposo , Imunidade
2.
Front Immunol ; 12: 611795, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33995344

RESUMO

Regulatory B cells (Bregs) is a term that encompasses all B cells that act to suppress immune responses. Bregs contribute to the maintenance of tolerance, limiting ongoing immune responses and reestablishing immune homeostasis. The important role of Bregs in restraining the pathology associated with exacerbated inflammatory responses in autoimmunity and graft rejection has been consistently demonstrated, while more recent studies have suggested a role for this population in other immune-related conditions, such as infections, allergy, cancer, and chronic metabolic diseases. Initial studies identified IL-10 as the hallmark of Breg function; nevertheless, the past decade has seen the discovery of other molecules utilized by human and murine B cells to regulate immune responses. This new arsenal includes other anti-inflammatory cytokines such IL-35 and TGF-ß, as well as cell surface proteins like CD1d and PD-L1. In this review, we examine the main suppressive mechanisms employed by these novel Breg populations. We also discuss recent evidence that helps to unravel previously unknown aspects of the phenotype, development, activation, and function of IL-10-producing Bregs, incorporating an overview on those questions that remain obscure.


Assuntos
Linfócitos B Reguladores/imunologia , Linfócitos B Reguladores/metabolismo , Imunomodulação , Animais , Subpopulações de Linfócitos B/metabolismo , Linfócitos B Reguladores/citologia , Biomarcadores , Diferenciação Celular , Citocinas/genética , Citocinas/metabolismo , Regulação da Expressão Gênica , Humanos , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo
3.
Nat Rev Nephrol ; 15(1): 11-26, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30443016

RESUMO

B cells have a central role in many autoimmune diseases, including in those with renal involvement, as well as in the immunological response to kidney transplantation. The majority of B cell studies have focused on their pathological role as antibody producers. However, these cells have broad functions in immune responses beyond immunoglobulin secretion, including antigen presentation to T cells and cytokine production. Importantly, not all B cell subsets enhance immune responses. Regulatory B (Breg) cells attenuate inflammation and contribute to the maintenance of immune tolerance. Breg cells are numerically deficient and/or dysfunctional in several autoimmune diseases that can affect the kidneys, including systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody-associated vasculitis, as well as in some groups of renal transplant recipients with alloimmune graft damage. B cell-targeting biologics have been trialled with promising results in diverse immune-mediated renal conditions. These therapies can affect both pro-inflammatory B cells and Breg cells, potentially limiting their long-term efficacy. Future strategies might involve the modulation of pro-inflammatory B cells in combination with the stimulation of regulatory subsets. Additionally, the monitoring of individual B cell subsets in patients may lead to the discovery of novel biomarkers that could help to predict disease relapse or progression.


Assuntos
Doenças Autoimunes/imunologia , Subpopulações de Linfócitos B/imunologia , Linfócitos B Reguladores/imunologia , Nefropatias/imunologia , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/metabolismo , Doenças Autoimunes/terapia , Fatores Biológicos/uso terapêutico , Biomarcadores/metabolismo , Humanos , Nefropatias/diagnóstico , Nefropatias/metabolismo , Nefropatias/terapia , Depleção Linfocítica/métodos
4.
Cell Rep ; 15(12): 2756-70, 2016 06 21.
Artigo em Inglês | MEDLINE | ID: mdl-27292648

RESUMO

The transcription factor T-bet directs Th1 cell differentiation, but the molecular mechanisms that underlie this lineage-specific gene regulation are not completely understood. Here, we show that T-bet acts through enhancers to allow the recruitment of Mediator and P-TEFb in the form of the super elongation complex (SEC). Th1 genes are occupied by H3K4me3 and RNA polymerase II in Th2 cells, while T-bet-mediated recruitment of P-TEFb in Th1 cells activates transcriptional elongation. P-TEFb is recruited to both genes and enhancers, where it activates enhancer RNA transcription. P-TEFb inhibition and Mediator and SEC knockdown selectively block activation of T-bet target genes, and P-TEFb inhibition abrogates Th1-associated experimental autoimmune uveitis. T-bet activity is independent of changes in NF-κB RelA and Brd4 binding, with T-bet- and NF-κB-mediated pathways instead converging to allow P-TEFb recruitment. These data provide insight into the mechanism through which lineage-specifying factors promote differentiation of alternative T cell fates.


Assuntos
Regulação da Expressão Gênica , Proteínas com Domínio T/metabolismo , Células Th1/metabolismo , Elongação da Transcrição Genética , Animais , Linhagem da Célula/genética , Elementos Facilitadores Genéticos/genética , Humanos , Camundongos Endogâmicos C57BL , Proteínas Nucleares/metabolismo , Fator B de Elongação Transcricional Positiva/metabolismo , Ligação Proteica/genética , RNA/genética , RNA/metabolismo , Células Th2/metabolismo , Fator de Transcrição RelA/metabolismo , Fatores de Transcrição/metabolismo , Uveíte/genética
5.
Nat Med ; 20(11): 1334-9, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25326801

RESUMO

Regulatory B cells (Breg cells) differentiate in response to inflammation and subsequently restrain excessive immune responses via the release of interleukin-10 (IL-10). However, the precise inflammatory signals governing their differentiation remain to be elucidated. Here we show that the gut microbiota promotes the differentiation of Breg cells in the spleen as well as in the mesenteric lymph nodes. Perturbation of the gut microbiome imposed either by antibiotic treatment or by changes in the sterility of housing conditions reduces the number and function of Breg cells. Following the induction of arthritis, IL-1ß and IL-6 are produced only in conventionally housed mice and both cytokines directly promote Breg cell differentiation and IL-10 production. Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a reduced number of IL-10-producing B cells and develop exacerbated arthritis compared to control animals. Thus, in response to inflammatory signals induced by both the gut flora and arthritis, Breg cells increase in number and restrain excessive inflammation.


Assuntos
Linfócitos B Reguladores/metabolismo , Trato Gastrointestinal/microbiologia , Interleucina-1beta/biossíntese , Interleucina-6/biossíntese , Microbiota , Animais , Antibacterianos/farmacologia , Artrite Experimental/imunologia , Artrite Experimental/patologia , Linfócitos B Reguladores/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Citometria de Fluxo , Trato Gastrointestinal/efeitos dos fármacos , Inflamação/patologia , Interleucina-10/biossíntese , Linfonodos/efeitos dos fármacos , Linfonodos/metabolismo , Camundongos Endogâmicos C57BL , Microbiota/efeitos dos fármacos , Organismos Livres de Patógenos Específicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA